• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Losardex Plus
    / Dexcel


    Active Ingredient *

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 x 12.5/50mg

    partial basket chart 82005 12424

    Related information


    Dosage

    Hypertension: Losartan and hydrochlorothiazide is not for use as initial therapy, but in patients whose blood pressure is not adequately controlled by losartan potassium or hydrochlorothiazide alone. Dose titration with the individual components (losartan and hydrochlorothiazide) is recommended.
    When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled.
    The usual maintenance dose of Losardex Plus is one tablet of Losardex Plus once daily. For patients who do not respond adequately to Losardex Plus, the dosage may be increased to two tablets of Losardex Plus once daily. The maximum dose is two tablets of Losardex Plus once daily. In general, the antihypertensive effect is attained within three to four weeks after initiation of therapy.
    Reduction in the risk of stroke in patients with hypertension and left ventricular hypertrophy: The usual starting dose is 50 mg of losartan once daily. If goal blood pressure is not reached with losartan 50 mg, therapy should be titrated using a combination of losartan and a low dose of hydrochlorothiazide (12.5 mg) and, if needed, the dose should then be increased to losartan 100 mg and hydrochlorothiazide 12.5 mg once daily. If necessary, the dose should be increased to losartan 100 mg and hydrochlorothiazide 25 mg once daily. Losardex Plus is a suitable alternative formulation in patients who would otherwise be treated concomitantly with losartan 50 mg plus hydrochlorothiazide 12.5 mg.
    Use in patients with renal impairment and haemodialysis patients: No initial dosage adjustment is necessary in patients with moderate renal impairment (i.e. creatinine clearance 30-50 ml/min). Losartan and hydrochlorothiazide tablets are not recommended for haemodialysis patients. Losardex Plus tablets must not be used in patients with severe renal impairment (i.e. creatinine clearance <30 ml/min).
    Use in patients with intravascular volume depletion: Volume and /or sodium depletion should be corrected prior to administration of Losardex Plus tablets.
    Use in patients with hepatic impairment: Losardex Plus is contraindicated in patients with severe hepatic impairment.
    Use in the elderly: Dosage adjustment is not usually necessary for the elderly.
    Use in children and adolescents (< 18 years): There is no experience in children and adolescents. Therefore, Losardex Plus should not be administered to children and adolescents.


    Indications

    Losardex plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate.
    To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.


    Contra-Indications

    – Hypersensitivity to losartan, sulphonamide-derived substances (as hydrochlorothiazide) or to any of the excipients.
    – Therapy resistant hypokalaemia or hypercalcaemia
    – Severe hepatic impairment; cholestasis and biliary obstructive disorders
    – Refractory hyponatraemia
    – Symtomatic hyperuricaemia/gout
    – 2nd and 3rd trimesters of pregnancy
    – Severe renal impairment (i.e. creatinine clearance <30 ml/min)
    – Anuria
    – The concomitant use of this formula with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2).
    See Lit.


    Special Precautions

    For additional information, please contact the license holder.


    Side Effects

    For additional information, please contact the license holder.


    Drug interactions

    For additional information, please contact the license holder.


    Pregnancy and Lactation

    For additional information, please contact the license holder.


    Overdose

    For additional information, please contact the license holder.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE